首页/数据集/Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer

Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer

NIAID Data Ecosystem2026-03-06 收录

结直肠癌化疗方案

结直肠癌治疗

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2055331 数据链接链接失效反馈

官方服务：

资源简介：

The aim of this study is to compare the activity and safety of Oxaliplatin and S-1 (OS) and Oxaliplatin and Capecitabine (XELOX) in patients with advance or recurrent colorectal cancer.

应用场景：

创建时间：

2008-04-15

结直肠癌治疗

药物剂量优化

Interventions: On Day 1, patients treated with FOLFIRI therapy received a 2-hour intravenous infusion of CPT-11 (150 mg/m2) combined with 1-LV (200 mg/m2), followed by a rapid intravenous infusion of

NIAID Data Ecosystem70

Discovery of 3,4-Dihydrobenzo[ f ][1,4]oxazepin-5(2 H )‑one Derivatives as a New Class of Selective TNIK Inhibitors and Evaluation of Their Anti-Colorectal Cancer Effects

TNIK抑制剂开发

结直肠癌治疗

The Traf2- and Nck-interacting protein kinase (TNIK) is a downstream signal protein of the Wnt/β-catenin pathway and has been thought of as a potential target for the treatment of colorectal cancer (C

NIAID Data Ecosystem50

Perioperative chemotherapy for locally advanced colorectal cancer.

结直肠癌化疗方案

围手术期治疗

Interventions: 1) All RAS wild-type: 6 courses of cetuximab+mFOLFOX6 or 4 courses of cetuximab+SOX is performed, followed by curative operarion. 2) All RAS mutant-type: 6 courses of FOLFOXIRI or SOXIR

NIAID Data Ecosystem30

Nutritional Status by Measurement the Sensitivity and Specificity for Some of Nutritional Indicators for Colorectal Cancer Patient Before and After Different Modulates of Treatment

营养评估

结直肠癌治疗

Nutritional Status by Measurement the Sensitivity and Specificity for Some of Nutritional Indicators for Colorectal Cancer Patient Before and After Different Modulates of Treatment

Global Health Data Exchange ()70

XELOX(+bevacizumab), efficacy, safety, QOL Study:FOLFOX(+bevacizumab) after starting therapy, for patients can’t continue continuous infusion therapy

结直肠癌化疗方案

抗肿瘤药物疗效评估

Interventions: 1000mg/m2 of oral Xeloda twice daily on days 1 through 14 every 3 weeks. L-OHP 130mg/m2 is administered intravenous injection on day 1. (Bevacizumab 7.5mg/kg is administered intravenous

NIAID Data Ecosystem40

Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer

资源简介：

相关数据集